Healthcare provider profile · identity verified

Alicia Jarrell

Nurse Practitioner · TUCSON, AZ · NPI 1639634884

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	307	42
Amlodipine Besylate	Amlodipine Besylate	241	34
Lisinopril	Lisinopril	237	39
Levothyroxine Sodium	Levothyroxine Sodium	235	35
Furosemide	Furosemide	209	31
Trazodone Hcl	Trazodone Hcl	205	26
Gabapentin	Gabapentin	169	24
Quetiapine Fumarate	Quetiapine Fumarate	167	21
Sertraline Hcl	Sertraline Hcl	165	21
Donepezil Hcl	Donepezil Hcl	154	22
Memantine Hcl	Memantine Hcl	130	23
Tamsulosin Hcl	Tamsulosin Hcl	129	16
Pantoprazole Sodium	Pantoprazole Sodium	124	18
Losartan Potassium	Losartan Potassium	123	21
Eliquis	Apixaban	117	20
Escitalopram Oxalate	Escitalopram Oxalate	117	18
Potassium Chloride	Potassium Chloride	108	20
Famotidine	Famotidine	102	16
Mirtazapine	Mirtazapine	97	18
Omeprazole	Omeprazole	91	16
Metformin Hcl	Metformin Hcl	90	13
Metoprolol Succinate	Metoprolol Succinate	78	11
Risperidone	Risperidone	69	11
Carvedilol	Carvedilol	68	15
Duloxetine Hcl	Duloxetine Hcl	65	suppressed
Simvastatin	Simvastatin	65	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	65	31
Hydrochlorothiazide	Hydrochlorothiazide	57	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	57	suppressed
Clonazepam	Clonazepam	56	13
Buspirone Hcl	Buspirone Hcl	54	13
Cephalexin	Cephalexin	51	18
Tramadol Hcl	Tramadol Hcl	50	12
Myrbetriq	Mirabegron	49	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	49	suppressed
Finasteride	Finasteride	46	suppressed
Pravastatin Sodium	Pravastatin Sodium	46	suppressed
Citalopram Hbr	Citalopram Hydrobromide	45	suppressed
Jardiance	Empagliflozin	45	suppressed
Spironolactone	Spironolactone	44	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	44	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	43	suppressed
Lorazepam	Lorazepam	40	15
Hydroxyzine Hcl	Hydroxyzine Hcl	39	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	37	26
Ropinirole Hcl	Ropinirole Hcl	36	suppressed
Divalproex Sodium	Divalproex Sodium	35	suppressed
Fluticasone Propionate	Fluticasone Propionate	35	15
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	35	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	33	suppressed
Lovastatin	Lovastatin	30	suppressed
Nystatin	Nystatin	30	18
Montelukast Sodium	Montelukast Sodium	29	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	28	suppressed
Doxepin Hcl	Doxepin Hcl	28	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	28	suppressed
Farxiga	Dapagliflozin Propanediol	27	suppressed
Glipizide	Glipizide	27	suppressed
Ibuprofen	Ibuprofen	27	suppressed
Levetiracetam	Levetiracetam	27	suppressed
Clopidogrel	Clopidogrel Bisulfate	26	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	25	suppressed
Alendronate Sodium	Alendronate Sodium	24	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	24	suppressed
Hydralazine Hcl	Hydralazine Hcl	24	suppressed
Allopurinol	Allopurinol	23	suppressed
Calcitriol	Calcitriol	23	suppressed
Cefdinir	Cefdinir	23	14
Midodrine Hcl	Midodrine Hcl	23	suppressed
Temazepam	Temazepam	23	suppressed
Bupropion Hcl Sr	Bupropion Hcl	22	suppressed
Bupropion Xl	Bupropion Hcl	22	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	22	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	21	suppressed
Oxycodone Hcl	Oxycodone Hcl	20	suppressed
Alprazolam	Alprazolam	19	suppressed
Divalproex Sodium Er	Divalproex Sodium	19	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	19	suppressed
Folic Acid	Folic Acid	19	suppressed
Amiodarone Hcl	Amiodarone Hcl	18	suppressed
Atenolol	Atenolol	18	suppressed
Methocarbamol	Methocarbamol	17	suppressed
Nyamyc	Nystatin	17	suppressed
Olanzapine	Olanzapine	17	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	16	11
Metformin Hcl Er	Metformin Hcl	16	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	15	suppressed
Baclofen	Baclofen	15	suppressed
Celecoxib	Celecoxib	15	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	15	suppressed
Fosfomycin Tromethamine	Fosfomycin Tromethamine	15	11
Lidocaine	Lidocaine	15	suppressed
Ondansetron Hcl	Ondansetron Hcl	15	suppressed
Pregabalin	Pregabalin	15	suppressed
Propranolol Hcl	Propranolol Hcl	15	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	15	suppressed
Letrozole	Letrozole	14	suppressed
Methylprednisolone	Methylprednisolone	14	14
Paroxetine Hcl	Paroxetine Hcl	14	suppressed
Ursodiol	Ursodiol	14	suppressed
Benztropine Mesylate	Benztropine Mesylate	13	suppressed
Meloxicam	Meloxicam	13	suppressed
Promethazine Hcl	Promethazine Hcl	13	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	13	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	12	suppressed
Haloperidol	Haloperidol	12	suppressed
Loperamide	Loperamide Hcl	12	suppressed
Memantine Hcl Er	Memantine Hcl	12	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	12	suppressed
Cholestyramine	Cholestyramine (With Sugar)	11	suppressed
Erythromycin	Erythromycin Base	11	suppressed
Levofloxacin	Levofloxacin	11	suppressed
Ondansetron Odt	Ondansetron	11	suppressed
Trintellix	Vortioxetine Hydrobromide	11	suppressed
Xarelto	Rivaroxaban	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error